| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.50▲ | 1.50▲ | 1.50▲ | 1.58▼ | 1.64▼ |
| MA10 | 1.51▲ | 1.55▼ | 1.55▼ | 1.61▼ | 1.84▼ |
| MA20 | 1.58▼ | 1.58▼ | 1.58▼ | 1.67▼ | 2.36▼ |
| MA50 | 1.65▼ | 1.67▼ | 1.66▼ | 1.95▼ | 1.81▼ |
| MA100 | 1.69▼ | 1.72▼ | 1.72▼ | 2.41▼ | 1.59▼ |
| MA200 | 1.75▼ | 1.93▼ | 2.06▼ | 1.94▼ | 1.72▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | -0.006▼ | -0.006▼ | 0.004▲ | -0.148▼ |
| RSI | 45.386▼ | 43.865▼ | 43.786▼ | 39.083▼ | 36.525▼ |
| STOCH | 36.356 | 28.557 | 28.557 | 25.210 | 9.187▼ |
| WILL %R | -51.852 | -56.667 | -59.248 | -74.349 | -93.315▼ |
| CCI | -11.844 | -44.412 | -45.108 | -128.393▼ | -91.571 |
|
Tuesday, December 02, 2025 04:59 AM
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for ...
|
|
Friday, October 24, 2025 04:44 PM
1 Day CMMB 11.68% DJIA 1.01% Russell 2K 1.24% Health Care/Life Sciences 0.29% ...
|
|
Sunday, June 29, 2025 05:00 PM
—Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Major Scientific Meetings— Dr. Mor concluded, “In ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/02/26 | 1.50 | 1.545 | 1.50 | 1.5303 | 33,155 |
| 05/02/26 | 1.59 | 1.64 | 1.42 | 1.45 | 87,591 |
| 04/02/26 | 1.68 | 1.68 | 1.55 | 1.63 | 52,627 |
| 03/02/26 | 1.695 | 1.74 | 1.59 | 1.62 | 106,351 |
| 02/02/26 | 1.618 | 1.729 | 1.5501 | 1.67 | 47,049 |
| 30/01/26 | 1.618 | 1.635 | 1.55 | 1.55 | 22,134 |
| 29/01/26 | 1.62 | 1.6856 | 1.525 | 1.57 | 64,377 |
| 28/01/26 | 1.70 | 1.74 | 1.60 | 1.62 | 39,108 |
| 27/01/26 | 1.80 | 1.8199 | 1.70 | 1.74 | 56,709 |
| 26/01/26 | 1.80 | 1.827 | 1.70 | 1.76 | 80,250 |
|
|
||||
|
|
||||
|
|